Teachers Advisors LLC increased its holdings in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 11.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,373 shares of the biotechnology company’s stock after purchasing an additional 3,446 shares during the quarter. Teachers Advisors LLC owned approximately 0.15% of Concert Pharmaceuticals worth $480,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Concert Pharmaceuticals by 0.6% during the first quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock worth $2,435,000 after purchasing an additional 838 shares during the last quarter. Alps Advisors Inc. lifted its stake in Concert Pharmaceuticals by 6.3% during the second quarter. Alps Advisors Inc. now owns 20,362 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 1,200 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Concert Pharmaceuticals by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 32,349 shares of the biotechnology company’s stock worth $552,000 after purchasing an additional 19,046 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Concert Pharmaceuticals by 27.5% in the first quarter. JPMorgan Chase & Co. now owns 52,783 shares of the biotechnology company’s stock valued at $900,000 after buying an additional 11,392 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its stake in Concert Pharmaceuticals by 68.7% in the second quarter. Fisher Asset Management LLC now owns 74,839 shares of the biotechnology company’s stock valued at $1,044,000 after buying an additional 30,476 shares during the last quarter. Hedge funds and other institutional investors own 62.52% of the company’s stock.

Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) opened at $17.53 on Friday. The company has a quick ratio of 17.50, a current ratio of 17.50 and a debt-to-equity ratio of 0.45. Concert Pharmaceuticals, Inc. has a twelve month low of $7.11 and a twelve month high of $19.11.

A number of equities research analysts have weighed in on CNCE shares. Stifel Nicolaus reiterated a “buy” rating and issued a $30.00 price objective on shares of Concert Pharmaceuticals in a research note on Sunday, October 22nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Concert Pharmaceuticals in a research note on Monday, September 18th. Zacks Investment Research cut Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Mizuho began coverage on Concert Pharmaceuticals in a research note on Thursday, October 26th. They set a “buy” rating and a $23.00 price target for the company. Finally, BidaskClub cut Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $23.00.

WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/12/concert-pharmaceuticals-inc-cnce-position-raised-by-teachers-advisors-llc.html.

In related news, insider Ryan Lynch sold 3,500 shares of the stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $14.51, for a total transaction of $50,785.00. Following the transaction, the insider now directly owns 9,500 shares in the company, valued at $137,845. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Value Fund L. P. Biotechnology bought 331,916 shares of Concert Pharmaceuticals stock in a transaction that occurred on Thursday, October 19th. The shares were acquired at an average price of $15.84 per share, for a total transaction of $5,257,549.44. The disclosure for this purchase can be found here. 10.10% of the stock is currently owned by corporate insiders.

Concert Pharmaceuticals Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Want to see what other hedge funds are holding CNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE).

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.